Conitec, a commission linked to the Ministry of Health, recommended this Wednesday (30) the incorporation of barictinib into the SUS for hospitalized adult patients with Covid-19.
Manufactured by the Lilly laboratory, the anti-inflammatory used mainly in the treatment of rheumatoid arthritis should be the first drug against Covid-19 offered in the public network against the new coronavirus.
Saúde still needs to publish an ordinance confirming the incorporation of the product.
The drug is to be delivered to adult, hospitalized patients “who require oxygen by mask or nasal catheter, or who require high flow oxygen or non-invasive ventilation,” according to an extract from the Conitec decision.
The government has not yet released an estimate of how many patients should receive the product and what the price should be for purchasing the drug.
Today the first generation of drugs against Covid-19 is found only in the private network.
In a note, Conitec reported that baricitinib acts on the immune system and helps in the process of recovery from inflammatory conditions.
“Studies have found that the use of baracitinib plus standard therapy (already adopted) contributed to a significant reduction in patient mortality compared to patients who received standard therapy alone,” the committee said.
Despite not yet having incorporated any new technology against Covid into the SUS, the Jair Bolsonaro government (PL) mobilized the pro-chloroquine wing at the Ministry of Health to boycott the discussion about vetoing the use of the “Covid kit” in the public network.
Baricitinib is registered in Brazil for the treatment of rheumatoid arthritis and atopic dermatitis. In September 2021, Anvisa (National Health Surveillance Agency) approved the indication against Covid-19.
Chad-98Weaver, a distinguished author at NewsBulletin247, excels in the craft of article writing. With a keen eye for detail and a penchant for storytelling, Chad delivers informative and engaging content that resonates with readers across various subjects. His contributions are a testament to his dedication and expertise in the field of journalism.
